# Hybrid Coronary Revascularization Trial

Study · id `cardio:ct-nct03089398` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03089398](<https://clinicaltrials.gov/study/NCT03089398>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03089398

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

## Technical summary

Registry record NCT03089398. Randomized; single masking; primary purpose treatment. Start 2017-10-09 (actual); primary completion 2021-03-31 (actual). Results posted on 2025-05-23.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 200 participants (enrolled count; ClinicalTrials.gov record NCT03089398, source copy `cardio:ctgov-nct03089398-2025-05-23`, retrieved 2026-10-26)
- Started: 2017-10-09 (actual) (ClinicalTrials.gov record NCT03089398, source copy `cardio:ctgov-nct03089398-2025-05-23`, retrieved 2026-10-26)
- Primary completion: 2021-03-31 (actual) (ClinicalTrials.gov record NCT03089398, source copy `cardio:ctgov-nct03089398-2025-05-23`, retrieved 2026-10-26)
- Completion: 2021-09-30 (actual) (ClinicalTrials.gov record NCT03089398, source copy `cardio:ctgov-nct03089398-2025-05-23`, retrieved 2026-10-26)
- Results first posted: 2025-05-23 (ClinicalTrials.gov record NCT03089398, source copy `cardio:ctgov-nct03089398-2025-05-23`, retrieved 2026-10-26)
- Countries: United States; Canada (ClinicalTrials.gov record NCT03089398, source copy `cardio:ctgov-nct03089398-2025-05-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03089398-2025-05-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Hybrid Coronary Revascularization Trial
- Condition: Coronary Artery Disease
- Intervention (Procedure): Hybrid Coronary Revascularization (isolated LIMA-LAD)
- Intervention (Device): Hybrid Coronary Revascularization (PCI)
- Intervention (Device): Percutaneous Coronary Intervention
- Lead sponsor: Emilia Bagiella
- Lead sponsor class: OTHER
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

## Provenance

Content hash: 52ac57a804630b42927127d0f60b6d5d6bcc5e03512e4c06c136b222a699f26f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
